Similarly, in the NCRI AML19 trial, the addition of GO to the fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin regimen (FLAG-Ida) significantly improved event-free survival (EFS) and reduced relapse rates, while also providing substantial overall survival (OS) benefits in patients with NPM1- and FLT3-mutated AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.